Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1985 Dec;52(6):863–866. doi: 10.1038/bjc.1985.270

Urinary pseudouridine excretion in myelomatosis.

S H Sørensen, D A Brown, E H Cooper, K A Kelly, I C MacLennan
PMCID: PMC1977279  PMID: 3907686

Abstract

Urinary psi excretion is independent of the main indices of tumour activity in myelomatosis (serum paraprotein, serum beta 2-microglobulin, serum creatinine and urinary light chain production). The mean (+/- s.d.) psi at presentation was 40.7 +/- 22.6 nmol. mumol ucr-1, compared to 25.4 +/- 4.8 nmol. mumol ucr-1 in controls. Urinary psi levels at presentation are significantly related to prognosis, the higher the level the poorer the prognosis. However, when these levels have been stratified according to the corresponding level of serum beta 2m, the level adds little as a prognostic factor.

Full text

PDF
863

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bataille R., Grenier J., Sany J. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients. Blood. 1984 Feb;63(2):468–476. [PubMed] [Google Scholar]
  2. Borek E., Sharma O. K., Waalkes T. P. New applications of urinary nucleoside markers. Recent Results Cancer Res. 1983;84:301–316. doi: 10.1007/978-3-642-81947-6_23. [DOI] [PubMed] [Google Scholar]
  3. Child J. A., Crawford S. M., Norfolk D. R., O'Quigley J., Scarffe J. H., Struthers L. P. Evaluation of serum beta 2-microglobulin as a prognostic indicator in myelomatosis. Br J Cancer. 1983 Jan;47(1):111–114. doi: 10.1038/bjc.1983.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cuzick J., Cooper E. H., MacLennan I. C. The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis. Br J Cancer. 1985 Jul;52(1):1–6. doi: 10.1038/bjc.1985.140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dirheimer G. Chemical nature, properties, location, and physiological and pathological variations of modified nucleosides in tRNAs. Recent Results Cancer Res. 1983;84:15–46. doi: 10.1007/978-3-642-81947-6_2. [DOI] [PubMed] [Google Scholar]
  6. Durie B. G., Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 Sep;36(3):842–854. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  7. Gehrke C. W., Kuo K. C., Davis G. E., Suits R. D., Waalkes T. P., Borek E. Quantitative high-performance liquid chromatography of nucleosides in biological materials. J Chromatogr. 1978 Mar 21;150(2):455–476. doi: 10.1016/s0021-9673(00)88205-9. [DOI] [PubMed] [Google Scholar]
  8. Heldman D. A., Grever M. R., Miser J. S., Trewyn R. W. Relationship of urinary excretion of modified nucleosides to disease status in childhood acute lymphoblastic leukemia. J Natl Cancer Inst. 1983 Aug;71(2):269–273. [PubMed] [Google Scholar]
  9. Heldman D. A., Grever M. R., Speicher C. E., Trewyn R. W. Urinary excretion of modified nucleosides in chronic myelogenous leukemia. J Lab Clin Med. 1983 May;101(5):783–792. [PubMed] [Google Scholar]
  10. Heldman D. A., Grever M. R., Trewyn R. W. Differential excretion of modified nucleosides in adult acute leukemia. Blood. 1983 Feb;61(2):291–296. [PubMed] [Google Scholar]
  11. Kuo K. C., Gehrke C. W., McCune R. A., Waalkes T. P., Borek E. Rapid, quantitative high-performance liquid column chromatography of pseudouridine. J Chromatogr. 1978 May 1;145(3):383–392. doi: 10.1016/s0378-4347(00)81367-5. [DOI] [PubMed] [Google Scholar]
  12. Nielsen H. R., Killmann S. A. Urinary excretion of beta-aminoisobutyrate and pseudouridine in acute and chronic myeloid leukemia. J Natl Cancer Inst. 1983 Nov;71(5):887–891. [PubMed] [Google Scholar]
  13. Rasmuson T., Björk G. R., Damber L., Holm S. E., Jacobsson L., Jeppsson A., Littbrand B., Stigbrand T., Westman G. Evaluation of carcinoembryonic antigen, tissue polypeptide antigen, placental alkaline phosphatase, and modified nucleosides as biological markers in malignant lymphomas. Recent Results Cancer Res. 1983;84:331–343. doi: 10.1007/978-3-642-81947-6_25. [DOI] [PubMed] [Google Scholar]
  14. Salvatore F., Colonna A., Costanzo F., Russo T., Esposito F., Cimino F. Modified nucleosides in body fluids of tumor-bearing patients. Recent Results Cancer Res. 1983;84:360–377. doi: 10.1007/978-3-642-81947-6_27. [DOI] [PubMed] [Google Scholar]
  15. Thomale J., Nass G. Increasing urinary levels of modified nucleosides and bases during tumor development in mice. Recent Results Cancer Res. 1983;84:378–387. doi: 10.1007/978-3-642-81947-6_28. [DOI] [PubMed] [Google Scholar]
  16. Tritsch G. L., Luch J. M., Evans J. T., Mittelman A. Age dependence of human urinary pseudouridine excretion. Biochem Med. 1979 Dec;22(3):387–390. doi: 10.1016/0006-2944(79)90027-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES